Earnings summaries and quarterly performance for WEST PHARMACEUTICAL SERVICES.
Executive leadership at WEST PHARMACEUTICAL SERVICES.
Eric Green
Detailed
President and Chief Executive Officer
CEO
AF
Annette Favorite
Senior Vice President, Chief Human Resources Officer
BB
Bernard Birkett
Senior Vice President, Chief Financial Officer
CW
Chad Winters
Vice President, Finance & Chief Accounting Officer
KM
Kimberly MacKay
Senior Vice President, General Counsel and Corporate Secretary
SC
Shane Campbell
Senior Vice President, Chief Proprietary Segment Officer
Board of directors at WEST PHARMACEUTICAL SERVICES.
DK
Deborah Keller
Detailed
Director
DM
Douglas Michels
Detailed
Director
JH
Janet Haugen
Detailed
Director
MB
Mark Buthman
Detailed
Director
MJ
Molly Joseph
Detailed
Director
ML
Myla Lai-Goldman
Detailed
Director
PP
Paolo Pucci
Detailed
Director
RF
Robert Friel
Detailed
Lead Independent Director
SL
Stephen Lockhart
Detailed
Director
TH
Thomas Hofmann
Detailed
Director
WF
William Feehery
Detailed
Director
Research analysts who have asked questions during WEST PHARMACEUTICAL SERVICES earnings calls.
JB
Justin Bowers
Deutsche Bank AG
8 questions for WST
Also covers: AMED, CON, CRL +9 more
Michael Ryskin
Bank of America Merrill Lynch
8 questions for WST
Also covers: A, ALGN, AVTR +28 more
Paul Knight
KeyBanc Capital Markets
8 questions for WST
Also covers: A, ATR, AVTR +16 more
Patrick Donnelly
Citi
7 questions for WST
Also covers: A, AVTR, BIO +22 more
DM
Daniel Markowitz
Evercore ISI
6 questions for WST
Also covers: INSP, RGEN, TECH
DL
Dan Leonard
UBS Group AG
5 questions for WST
Also covers: A, AVTR, BIO +11 more
DW
David Windley
Jefferies Financial Group Inc.
5 questions for WST
Also covers: CERT, CNC, CRL +15 more
Doug Schenkel
Wolfe Research LLC
5 questions for WST
Also covers: A, AVTR, BRKR +16 more
ML
Matthew Larew
William Blair & Company
5 questions for WST
Also covers: AMED, ATR, DNA +10 more
LS
Larry Solow
CJS Securities
3 questions for WST
Also covers: ARCB, BTSG, CDRE +14 more
LS
Lawrence Solow
CJS Securities, Inc.
3 questions for WST
Also covers: BTSG, CDRE, CLH +13 more
ML
Matt Larew
William Blair & Co.
3 questions for WST
Also covers: AMED, ATR, AVTR +10 more
Thomas DeBourcy
Nephron Research
3 questions for WST
Also covers: CDNA, NEOG, QTRX +2 more
Tucker Remmers
Jefferies
3 questions for WST
Also covers: FTRE, VEEV
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
2 questions for WST
Also covers: ABCL, ABSI, ARWR +20 more
JJ
Jacob Johnson
Stephens Inc.
2 questions for WST
Also covers: AZTA, CDMO, CDXS +11 more
Luke Sergott
Barclays
2 questions for WST
Also covers: A, AVTR, BRKR +19 more
ME
Matt Etoch
Stephens Inc
2 questions for WST
Douglas Schenkel
Wolfe Research, LLC
1 question for WST
Also covers: A, AVTR, BRKR +21 more
KC
Kyle Cruise
UBS
1 question for WST
Also covers: CRL
Mac Etoch
Stephens Inc.
1 question for WST
Also covers: AZTA, CYRX, RGEN +5 more
ME
Mac Etosh
Stephens
1 question for WST
Salem Salem
Barclays
1 question for WST
Also covers: GH, IQV, PACB +3 more
TD
Thomas Diversey
Nippon Research
1 question for WST
Tom DeBourcy
Nephron Research LLC
1 question for WST
Also covers: CDNA, NEOG, RGEN +2 more
Recent press releases and 8-K filings for WST.
West Pharmaceutical Services reports Q4 2025 results
WST
Earnings
Guidance Update
Product Launch
- Q4 revenues of $805 million (+7.5% reported, +3.3% organic), adjusted EPS of $2.04 (+12% YoY), and free cash flow of $175 million (more than double prior year).
- High-value product (HVP) components drove growth—48% of net sales, with Q4 revenue of $390 million (+15.1% organic); HVP delivery devices at $110 million (‐18.1% organic), standard products $162 million (‐1.7%), and contract manufacturing $143 million (+1.9%) in Q4.
- 2026 guidance: revenues of $3.215 billion–$3.275 billion (organic growth 5–7%), with HVP components up high single- to low double-digits and GLP-1s ~10%; CapEx of $250 million–$275 million.
- Launched the West Synchrony Prefillable Syringe System—offering a full verified platform and comprehensive performance/regulatory data to accelerate syringe selection for biologics.
- Initiated over 700 Annex 1 upgrade projects (65 completed in Q4), representing <15% of a 6 billion-unit upgrade opportunity; these are expected to drive ~200 bps of additional growth in 2026.
6 days ago
West Pharmaceutical Services reports Q4 2025 results
WST
Earnings
Guidance Update
Product Launch
- West delivered Q4 revenues of $805 million, up 7.5% reported and 3.3% organically; Adjusted EPS of $2.04 (+12% y/y), and free cash flow of $175 million, more than double prior year.
- For full year 2025, net sales surpassed $3 billion with over 4% organic growth, 8% adjusted EPS growth, and 70% free cash flow increase.
- HVP components led growth with $390 million revenue (+15.1% organic); contract manufacturing revenues of $143 million (+1.9% organic); standard products at $162 million (-1.7% organic).
- Launched the West Synchrony Prefillable Syringe System and announced sale of the SmartDose 3.5 mL business, expected to close mid-2026.
- 2026 guidance calls for 5–7% organic revenue growth and 10% adjusted EPS growth at the midpoint.
6 days ago
West Pharmaceutical Services reports Q4 2025 results
WST
Earnings
Guidance Update
- Net sales of $805.0 M in 4Q25, up 7.5% YoY (3.3% organic); gross margin expanded to 37.8% (+130 bps).
- Adjusted operating profit margin of 21.4% (–30 bps) and adjusted diluted EPS of $2.04, up 12.1% vs. 4Q24.
- Operating cash flow of $251.1 M (+32.1% YoY) and free cash flow of $175.0 M (+105.2% YoY).
- 1Q26 guidance: revenue of $770 M–$790 M with 4.6%–7.4% organic growth and adjusted EPS of $1.65–$1.70.
6 days ago
West Pharmaceutical Services reports Q4 2025 results
WST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Q4 revenue of $805 million, up 7.5% reported and 3.3% organic; HVP components drove growth with $390 million (+15.1%), while delivery devices were $110 million (–18.1%), standard products $162 million (–1.7%) and contract manufacturing $143 million (+1.9%).
- Gross margin expanded to 37.8% (+130 bps) and adjusted operating margin was 21.4%, supporting Q4 adjusted EPS of $2.04 (+12.1%).
- Full-year 2025 free cash flow reached $469 million (+70%), with CapEx of $286 million; 2026 CapEx is guided down to $250 – 275 million.
- 2026 guidance: revenues of $3.215 – 3.275 billion for 5 – 7% organic growth; HVP components to grow high-single to low-double digits, GLP-1 elastomers ~10%, standard products flat and contract manufacturing flat.
6 days ago
West Pharmaceutical Services reports Q4 and FY2025 results
WST
Earnings
Guidance Update
Share Buyback
- Fourth-quarter net sales of $805.0 million, up 7.5% year-over-year; diluted EPS $1.82 (+2.2%) and adjusted EPS $2.04 (+12.1%).
- Full-year net sales of $3.074 billion, up 6.3%; diluted EPS $6.79 (+1.5%) and adjusted EPS $7.29 (+8.0%).
- Operating cash flow of $754.8 million (+15.5%), free cash flow of $468.9 million (+69.6%), and capital expenditures of $285.9 million.
- Repurchased 552,593 shares for $134.0 million at an average price of $242.55 under its share buyback program.
- Introduced 2026 guidance calling for net sales of $3.215 billion to $3.275 billion and adjusted EPS of $7.85 to $8.20.
6 days ago
West Pharmaceutical Services reports Q4 and full-year 2025 results
WST
Earnings
Share Buyback
- Fourth-quarter net sales were $805.0 million, up 7.5% year-over-year with 3.3% organic growth.
- Fourth-quarter diluted EPS was $1.82 (+2.2%), and adjusted-diluted EPS was $2.04 (+12.1%).
- Full-year 2025 net sales reached $3.074 billion (+6.3%; organic +4.3%), with diluted EPS of $6.79 (+1.5%) and adjusted-diluted EPS of $7.29 (+8.0%).
- Operating cash flow was $754.8 million (+15.5%) and free cash flow $468.9 million (+69.6%); the company repurchased 552,593 shares for $134.0 million.
- In Q4, HVP Components net sales grew 20.3% (organic +15.1%) and Contract-Manufactured Products sales grew 6.2% (organic +1.9%).
6 days ago
West outlines 7–9% organic growth target and strategic priorities at J.P. Morgan
WST
Guidance Update
- West reiterated 7–9% long-term organic revenue growth and 100+ bps operating margin expansion underpinned by a mix shift toward high-value products.
- High-value product (HVP) components comprised 48% of revenue in Q3 2025 (up from 42% in 2019) and generated over 70% of gross profit, with HVP penetration expected to expand further.
- Key growth drivers include biologics & biosimilars (40% of revenue; 90% participation in new approvals), GLP-1 injectables (9% of revenue in elastomers; 8% in contract manufacturing), and Annex 1 regulatory adoption adding ~200 bps to HVP growth in 2025.
- Announced sale of the SmartDose device business (<4% of sales) to AbbVie to refocus on higher-growth HVP components, with proceeds to support organic investments and shareholder returns.
Jan 14, 2026, 5:00 PM
West Pharmaceutical outlines growth strategy and financial outlook
WST
Guidance Update
M&A
- West is a global leader in injectables with $2.9 B net sales and 19.8% adjusted operating margin in FY 2024.
- Targeting 7–9% organic revenue growth and ~100 bps annual margin expansion, driven by high-value components, biologics, GLP-1 demand, and Annex 1 regulations.
- Strong cash generation: $594 M operating cash flow and $294 M free cash flow for YTD September 2025, with CapEx normalized at 6–8% of revenues and a net cash position.
- Agreed to sell SmartDose 3.5 mL On-Body Delivery System manufacturing rights to AbbVie for $112.5 M, expected to close mid-2026.
Jan 14, 2026, 5:00 PM
West Pharma outlines growth strategy and targets at J.P. Morgan Healthcare Conference
WST
Guidance Update
- West Pharma is the global leader in injectable medicines, producing 41 billion components annually, generating c. $3 billion revenue in 2024 and touching 100 million patients daily.
- The company targets 7–9% organic revenue growth and 100+ bps operating margin expansion, driven by mix shift toward high-value product (HVP) components (48% of revenue in Q3 2025) and growth in biologics/biosimilars, GLP-1 injectables, and Annex 1 regulatory upgrades.
- HVP components grew 13.3% organically in Q3 2025, supported by new biologics launches, rising GLP-1 injectable adoption (9% of revenue), and regulatory-driven packaging upgrades in Europe.
- West remains net cash positive with strong free cash flow (up ~54% y/y for first 9 months 2025) and plans to normalize CapEx to 6–8% of sales starting 2026, prioritizing high-value investments and shareholder returns.
- The company will divest its SmartDose device business to AbbVie (<4% of sales) to redeploy resources into higher-growth segments while maintaining customer partnerships.
Jan 14, 2026, 5:00 PM
West outlines 2026 growth strategy at J.P. Morgan Healthcare Conference
WST
Guidance Update
M&A
New Projects/Investments
- West is the global leader in injectable medicines with ~$3 billion revenue in 2024, 20% operating margin, 25 manufacturing sites, and 41 billion components produced annually, touching 100 million patients daily.
- The company targets 7%–9% organic revenue growth and 100+ basis points of operating margin expansion, driven by a mixed-shift toward high-value product (HVP) components.
- HVP components comprised 48% of Q3 2025 revenues and generated >70% of gross profit (up from 42% in 2019), underpinned by biologics (40% of revenues, 90% participation in 2025 approvals), GLP-1 injectables (9% of revenues), and Annex 1 conversions adding ~200 bps in 2025.
- West will reduce CapEx to 6%–8% of sales by 2026, leverage ~60% utilization in HVP plants, maintain a net cash position, and pursue disciplined organic investments and selective M&A to deploy excess cash.
- The company agreed to sell its SmartDose platform to AbbVie (representing <4% of sales) to reallocate resources to faster-growing HVP components.
Jan 14, 2026, 5:00 PM
Fintool News
In-depth analysis and coverage of WEST PHARMACEUTICAL SERVICES.
Quarterly earnings call transcripts for WEST PHARMACEUTICAL SERVICES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more